AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06276400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS Stimulation
Description: FPl vs. mid-LPFC vs. non-PFC Control (S1); Specific LPFC region (vs. non-PFC active Control) function is manipulated with an inhibitory TMS protocol (cTBS).
Study NCT06402942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified occupational therapy programme
Description: Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
Study NCT06402942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classic occupational therapy programme
Description: Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
Study NCT06056089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ready-to-use supplementary food (RUSF)
Description: standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/media/16636/file/S0000248-RUSF-Specification.pdf
Study NCT06056089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use therapeutic food (RUTF)
Description: standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
Study NCT05864118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory pathogen panel PCR test
Description: Respiratory pathogen panel PCR test and COVID-19 antibody test.
Study NCT05864118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 antibody test
Description: COVID-19 antibody test
Study NCT04437498 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: non invasive vagal nerve stimulation
Study NCT04437498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nVNS
Description: active vns stimulation
Study NCT05693909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: Capsules for oral intake
Study NCT06401278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: It will be performed by using the TENS device on acupoint (TEAS) as the following:~The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)
Study NCT06401278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (group b):
Description: TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
Study NCT04689074 — intervention group
Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
Study NCT04689074 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
Study NCT05525247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-3010
Description: Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
Study NCT04689074 — intervention group
Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study NCT06283407 — intervention group
Intervention type: OTHER
Intervention: ICF-based cross-country comparative analysis
Description: ICF-based cross-country comparative analysis
Study NCT05854849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, D1, Q3W, iv drip.
Study NCT05854849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: 200mg, D1, Q3W, iv drip.
Study NCT05854849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.
Study NCT05854849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.
Study NCT05854849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m2, D1, Q3W, iv drip, maximum 6 cycles.
Study NCT05854849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg, PO, QD
Study NCT05525247 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle
Study NCT01540604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD007
Study NCT05359055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet
Description: 100mg once daily on Day 1 and Day 8
Study NCT05359055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200mg once daily from Day 3 to Day10.
Study NCT05359055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet
Description: 200mg once daily on Day 1 and Day 12.
Study NCT05359055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600mg once daily from Day 3 to Day13.
Study NCT05142930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent ultrasound
Description: Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region
Study NCT05142930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous ultrasound
Description: Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region
Study NCT05803083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid 75 mg/capsule
Description: Take 2 capsules per day at any time.
Study NCT05803083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid 50 mg/capsule
Description: Take 2 capsules per day at any time.
Study NCT05803083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 2 capsules per day at any time.
Study NCT05728190 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: steril/salin water
Description: Five days seven drops of saline/sterile water were dripped onto a 5x5 gauze pad in the morning and evening, and they were put to sniff for 20 minutes, 10 cm away from the nose. Green food coloring was added (one drop of food coloring to 5 ml of sterile/saline water) to make sterile/saline water similar to lavender oil.
Study NCT05728190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Description: Five days seven drops of lavender essential oil were dripped onto a 5x5 gauze pad in the morning and evening, for 20 minutes, 10 cm away from the nose, and sniffed.
Study NCT06177899 — intervention group
Intervention type: PROCEDURE
Intervention: Splitting of bone and fixation of bone laminae differ between the 3 groups.
Description: In split-box technique, all osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. In reverse split box technique, differs from the split-box technique as follows: it involves reversing the separated corticocancellous bone block before fixation. In sliding split box technique, differs from the split-box technique as follows: horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone.
Study NCT04799769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous arterial closure device
Description: Large hole percutaneous arterial closure device
Study NCT05032404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BNT103
Description: BNT-103™ is a prescription digital therapeutic specifically designed to treat the symptoms of anxiety and depression related to cancer. There are 10 sessions provided over approximately 10 weeks.
Study NCT01194193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8055
Description: Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
Study NCT04842552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine hydrochloride 25mg tablets
Description: Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
Study NCT04842552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05923346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLUTLEARN
Description: The group will be made up of users of the social network Instagram who have celiac disease or are close to a celiac patient (parent/guardian of celiac children or cohabitants).~The intervention will be carried out through the social network Instagram. Participants will be recruited through the same social network. Participants must agree to take part in the study.~The educational intervention will be carried out for one month, where each day a post will be uploaded with specific, truthful and current information. The content of the intervention has been divided into 5 main blocks: 1) general concepts about CD, 2) balanced GFD, 3) food labelling, 4) cross-contact/cross-contamination, 5) new research on CD and useful resources for disease management.
Study NCT04855942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Extracorporeal Shock Wave Therapy (ESWT)
Description: 2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
Study NCT04855942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: therapeutic ultrasound, 12 times in 3 weeks
Study NCT05617963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients showing a disease control (defined as stable disease \[SD\], partial response \[PR\], or complete response \[CR\] according to RECIST v1.1) at the radiological evaluation performed after the end of thoracic CRT will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death or patient's decision for a maximum of 24 months.
Study NCT04990765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Behavioral Therapy (CRAVR)
Description: Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
Study NCT04990765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.
Study NCT04334278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetHealthy-OA
Description: The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
Study NCT04334278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth.
Study NCT04790864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online large-group one-session treatment with post-treatment exercise targeting expectancy violation
Description: The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet with questions aimed at enhancing the processing of what was learned during treatment in terms of expectancy violation. For example, they are asked if what they were most worried about occured and what actually happened compared to what they predicted to happen. This should highlight the discrepancy between anticipated and actual outcomes. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
Study NCT04790864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online large-group one-session treatment with post-treatment control exercise
Description: The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet that addresses basic contentual information concerning the treatment without a specific attempt to highlight the discrepancy between anticipated and actual outcomes. For example, participants will be asked how they would explain public speaking anxiety and exposure therapy to a friend and what advantages they see in conducting treatments like this in groups. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
Study NCT05663528 — intervention group
Intervention type: PROCEDURE
Intervention: orotracheal intubation
Description: Clinical and laboratory data will be collected from patients who are intubated after 48 hours of admission to the intensive care unit
Study NCT00954200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: ibuprofen 10mg/kg syrup, single dose vs placebo
Study NCT00954200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibuprofen
Description: 10mg/kg syrup - single dose
Study NCT00954200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: 10mg/kg syrup - single dose
Study NCT05060107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exosomes (sEVs)
Description: Exosomes 3-5x10e11 particles/dose
Study NCT05216640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen Therapy
Description: • The patient will be allocated into 2 groups, patients who will require ventilatory support via HFNC and those who will require HVNI
Study NCT05136430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation strategies + large changes (SR)
Description: The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on teaching self-regulation and efforts to produce a 10 lb weight loss to buffer against anticipated post-cessation weight gain. Participants will be taught the core self-regulation skills for controlling their weight. In order to produce an initial weight loss buffer, they will be instructed to self-monitor their intake, given a daily calorie goal, and taught strategies for reducing caloric intake. Structured physical activity, such as brisk walking will also be prescribed and self-monitored. During smoking cessation treatment (weeks 9-16), participants will be asked to continue to use self-regulation skills for monitoring their weight and to use a color zone system (red, yellow, green) to determine what course of action to follow based on whether changes in weight have occurred.
Study NCT05136430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Education (LE)
Description: The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on living a healthy lifestyle. Information provided will include education on why weight gain happens while quitting smoking, principles of healthy eating (e.g., simple versus complex carbohydrates), physical activity guidelines, and other topics related to living a healthy lifestyle. Participants can choose to use the healthy lifestyle information and education provided however they would like. Participants will not be asked to use self-regulation strategies during either part of the 16-week program.
Study NCT05136430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Treatment
Description: The second 8 weeks (weeks 9-16) of the 16-week program will include weekly group counseling sessions focused on smoking cessation. The smoking cessation treatment provided will be the same in both arms of the study. In preparation of quitting, nicotine replacement therapy lozenges will be provided for 3 weeks prior to quitting (weeks 6-8). A group quit day will occur on week 9. During the smoking cessation portion of treatment (weeks 9-16), participants will be provided with combination nicotine replacement therapy (patches + lozenges) and daily supportive text messages.
Study NCT05136430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Treatment
Description: The second 8 weeks (weeks 9-16) of the 16-week program will include weekly group counseling sessions focused on smoking cessation. The smoking cessation treatment provided will be the same in both arms of the study. In preparation of quitting, nicotine replacement therapy lozenges will be provided for 3 weeks prior to quitting (weeks 6-8). A group quit day will occur on week 9. During the smoking cessation portion of treatment (weeks 9-16), participants will be provided with combination nicotine replacement therapy (patches + lozenges) and daily supportive text messages.
Study NCT06269159 — intervention group
Intervention type: OTHER
Intervention: Concept mapping: brainstorm
Description: Group health care providers:~* Duration: 1.5 hour for HCP via zoom session~* Brainstorm question: what would help your clients to change their sedentary behavior into more physical activity?~Group adults with overweight and obesity~* Duration: online survey (REDCAP) of approx. 10 minutes~* Brainstorm question via an online survey. What would help you to change your sedentary behavior into more physical activity?
Study NCT06269159 — intervention group
Intervention type: OTHER
Intervention: Concept mapping: clustering and rating
Description: The same participant of the brainstorm session are asked to join session 2 to complete the clustering and rating). All interested adults will get access to the online cluster and rate tool described below.~* Duration: flexible use of the online tool (available for two weeks)~* The clustering and rating of all needs mentioned in session 1 will be done online and individually via a web application. In this online tool, the final list of 'needs' generated in session 1 will be presented.~* Individually sort the 'needs' into groups and give the group a theme. In addition, each need will be scored on effectiviness, feasibility, modifiability. Thhe participants have unlimited access for two weeks.
Study NCT06164808 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HeartWatch
Description: The HeartWatch is indicated for the extended diagnostic evaluation of patients with symptomatic and transient symptoms such as light-headedness, syncope, and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. It is an armband consisting of the main body of the device with an additional sensor located on the band. It is worn around the upper left arm to obtain heart electrical signals. The device is paired with the HelpWear application on a smartphone where the signals are stored and then will be uploaded to a secure network for analysis.
Study NCT05625347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose (100 mg) of ASA
Description: powder for oral inhalation via a Dry Powder Inhaler (DPI)
Study NCT05625347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Description: orally administered